MA-INVICRO
23.12.2019 16:04:07 CET | Business Wire | Press release
Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership responsibilities of the Company and will join Invicro’s Board of Directors, effective immediately. Dr. Jack Hoppin, co-founder of Invicro, will move on from his role as Invicro’s CEO to be the President of Konica Minolta Precision Medicine (KMPM). Dr. Hoppin will remain on Invicro’s Board of Directors, as well as continue to serve on the KMPM Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191223005320/en/
Konica Minolta, Inc. acquired Invicro LLC and Ambry Genetics Corporation in September 2017 to accelerate its strategic vision to transform personalized medicine through the delivery of diagnostic services via genetics, imaging and digital pathology capabilities. Konica Minolta Precision Medicine was formalized as a result of bringing these three entities together.
“It has been an extreme honor to serve as Invicro’s CEO, since co-founding the company in 2008,” stated Dr. Hoppin. “This is an exciting time for Invicro, Ambry and KMPM, as we are all working together to support the medical research community through integrated AI technology platforms that allow molecular-level testing and analysis offering insights to advance translational medicine.”
In his new role, Dr. Hoppin will work to synergize the companies under KMPM to help pharmaceutical sponsors and clinicians accelerate the development of targeted therapies through genetic and molecular profiling.
“I’m looking forward to seeing the next chapter for KMPM and Invicro,” said Mr. Kiyotaka Fujii, president of Konica Minolta Global Healthcare and CEO of KMPM. “As KMPM continues to focus on revolutionizing personalized healthcare via the strengths of Konica Minolta, Invicro and Ambry, Jack will be instrumental in leading and realizing the Konica Minolta Precision Medicine mission. I have full confidence that Matt will seamlessly transition to his new role and continue to lead Invicro into new breakthroughs that will help advance the discovery and development of life-changing medicines.”
Dr. Silva will carry on Invicro’s strategic mission to support the drug discovery and development community. Invicro will continue to leverage its industry-leading imaging, chemistry, and analysis expertise that span discovery through clinical research across multiple therapeutic areas, including the central nervous system, oncology, rare disease, and other systemic diseases. Further, Invicro will continue to invest in its data informatics platforms, enabling management, visualization, and analysis of pathological and radiological imaging data and ensuring alignment with KMPM.
“First, I want to thank Jack for leading Invicro to the great success it is today. I’m honored, humbled and extremely excited to assume this new role and carry on the mission,” said Dr. Silva. “It’s an exciting time for Invicro, as we continue to make great strides with our pharma services capabilities offering imaging biomarkers, advanced analytics, innovative chemistry and technologies, and global core lab services. Thanks to Invicro’s dedicated team and our pharma sponsors—we are together helping the development of new medicines that will improve the lives of patients in need.”
With 20 years of diverse imaging experience, Dr. Silva first joined Invicro in 2012 and most recently was EVP of Scientific Applications, where he led strategic efforts to expand the clinical oncology drug development and clinical trials. Dr. Silva’s pharma industry experience includes scientific and leadership positions at Vertex, Amgen, Millennium and Takeda Pharmaceuticals. Dr. Silva holds a Ph.D. and a Master’s degree in Biomedical Engineering from Worcester Polytechnic Institute.
About Invicro
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. For more information, visit www.invicro.com .
About Konica Minolta Precision Medicine
Konica Minolta Precision Medicine, Inc. (“KMPM”) based in Aliso Viejo, CA is a subsidiary of Konica Minolta, Inc. that includes Ambry Genetics Corporation and Invicro LLC. Founded in 2018 on the belief that groundbreaking medical breakthroughs are possible by concentrating efforts on the health expression map, the undiscovered territory between an individual’s genetics and biological impacts, and quantifiably measuring health over time. KMPM’s health intelligence and visualization platform brings together the most novel and diverse set of data from genes, proteins, cells and tissues with sophisticated analytics and world-leading scientific and medical expertise, enabling more prescriptive, proactive and preventive care. For further information, visit: www.KonicaMinoltaPrecisionMedicine.com
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20191223005320/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase Open Control Plane Innovations for AI Infrastructure at OCP Global Summit 202628.9.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its participation in OCP Global Summit 2026. At the event, Lattice and AMI, a Lattice company, will demonstrate how an open control plane can help organizations build secure, scalable, and manageable AI infrastructure from silicon to rack. During the event, Lattice will deliver keynote and technical presentations, showcase open management and control solutions, and host interactive demonstrations highlighting secure platform firmware, infrastructure manageability, AI rack management, quantum-resistant security, connectivity, and modular rack-scale architectures. Together, Lattice and AMI technologies will be in full display, demonstrating how organizations can build open, interoperable infrastructure capable of supporting the growing demands of AI data centers. Who: Lattice Semiconductor and AMI, a Lattice Company What / When:Keynote Presentation – “The Open Control Plane: Fro
SLB Announces Date for Third-Quarter 2026 Results Conference Call28.9.2026 19:17:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on October 23, 2026, to discuss the results for the third quarter ending September 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/293449855 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until October 30, 2026, and can be accessed by dialing +1 (800) 770-2030 within North Amer
Boomi Named a Leader and Secures Highest Score in the Strategy Category in Adaptive Process Orchestration Software Evaluation28.9.2026 17:45:00 CEST | Press release
Boomi recognized as a Leader in evaluation of agentic process orchestration software Boomi™, the data activation company for AI, today announced it has been named a Leader in The Forrester Wave™: Adaptive Process Orchestration Software, Q3 2026. The report evaluated 13 providers, and Boomi achieved the highest score in the strategy category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928931590/en/ Boomi Named a Leader and Secures Highest Score in the Strategy Category in Adaptive Process Orchestration Software Evaluation According to the report, Boomi’s “above-par roadmap is driven by a strong internal innovation process that embraces partner input and customer feedback, while recent investments focus on supporting client data sovereignty and control in geographies where sovereignty matters.” The report also cites Boomi's vendor-neutral control plane for agentic automation as allowing it to extend into the process aut
Azalea Vision Enrolls First Patient in Proof-of-Concept Study Evaluating Novel Optical Aperture for Keratoconus and Presbyopia28.9.2026 16:27:00 CEST | Press release
Azalea Vision has enrolled the first patient in its NOA proof-of-concept study, launching the company’s clinical program. The study evaluates a Novel Optical Aperture (NOA) inside a contact lens in two patient groups, keratoconus and presbyopia. Clinical study results are expected to inform the planned first-in-human evaluation of Azalea’s fully integrated smart contact lens platform in Europe and the United States. Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced that it has enrolled the first patient in its NOA proof-of-concept study. The study marks the start of Azalea’s clinical program, following its selection for the European Innovation Council (EIC) Accelerator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928982998/en/ Novel Optical Aperture smart lens The study is conducted at Visser Contact Lenses (Netherlands) and the University Hospital Antwerp
Xsolla Releases The Xsolla Report: Mobile D2C Edition28.9.2026 15:00:00 CEST | Press release
New Data From More Than 800 Mobile Web Shops Finds Direct-to-Consumer Has Become a Standard Operating Discipline, With Top Performers Capturing More Than Half of a Title's Revenue Regardless of Studio Size Xsolla, a global commerce company, today released The Xsolla Report: Mobile D2C Edition, a new study examining how direct-to-consumer commerce is performing across mobile games. Drawing on data from more than 800 live Xsolla Web Shops alongside public market and regulatory data, the report shows that D2C has moved past the question of whether it works and into a new phase: studios seeing the strongest results are the ones treating their Web Shop as an operating discipline rather than a one-time build. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928312597/en/ Graphic: Xsolla Three themes run through the report. First, the gap between a typical Web Shop and a top-performing one is wide, and closing it has little to do
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom